VIGL vs. BLUE, ALVR, CRIS, LIFE, SGMO, BCAB, PLX, ATRA, OTLK, and PASG
Should you be buying Vigil Neuroscience stock or one of its competitors? The main competitors of Vigil Neuroscience include bluebird bio (BLUE), AlloVir (ALVR), Curis (CRIS), aTyr Pharma (LIFE), Sangamo Therapeutics (SGMO), BioAtla (BCAB), Protalix BioTherapeutics (PLX), Atara Biotherapeutics (ATRA), Outlook Therapeutics (OTLK), and Passage Bio (PASG). These companies are all part of the "biological products, except diagnostic" industry.
Vigil Neuroscience (NASDAQ:VIGL) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.
Vigil Neuroscience has higher earnings, but lower revenue than bluebird bio. Vigil Neuroscience is trading at a lower price-to-earnings ratio than bluebird bio, indicating that it is currently the more affordable of the two stocks.
Vigil Neuroscience has a net margin of 0.00% compared to bluebird bio's net margin of -419.64%. bluebird bio's return on equity of -34.32% beat Vigil Neuroscience's return on equity.
Vigil Neuroscience presently has a consensus price target of $17.20, suggesting a potential upside of 355.03%. bluebird bio has a consensus price target of $5.74, suggesting a potential upside of 489.42%. Given bluebird bio's higher probable upside, analysts plainly believe bluebird bio is more favorable than Vigil Neuroscience.
83.6% of Vigil Neuroscience shares are held by institutional investors. Comparatively, 87.4% of bluebird bio shares are held by institutional investors. 33.5% of Vigil Neuroscience shares are held by insiders. Comparatively, 2.1% of bluebird bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Vigil Neuroscience has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
In the previous week, bluebird bio had 6 more articles in the media than Vigil Neuroscience. MarketBeat recorded 16 mentions for bluebird bio and 10 mentions for Vigil Neuroscience. Vigil Neuroscience's average media sentiment score of 0.61 beat bluebird bio's score of 0.09 indicating that Vigil Neuroscience is being referred to more favorably in the media.
bluebird bio received 1017 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 75.00% of users gave Vigil Neuroscience an outperform vote while only 71.78% of users gave bluebird bio an outperform vote.
Summary
bluebird bio beats Vigil Neuroscience on 10 of the 17 factors compared between the two stocks.
Get Vigil Neuroscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vigil Neuroscience Competitors List
Related Companies and Tools
